Moderna reports second quarter 2023 financial results and provides business updates

Second quarter 2023 revenues of $0.3 billion; net loss of $1.4 billion and loss per share of $3.62 company expecting 2023 covid-19 vaccine sales of $6 billion to $8 billion, dependent on u.s. vaccination rates company submitted its investigational rsv vaccine to several regulators globally ahead of potential 2024 launch with its partner merck, the company began phase 3 trial of mrna-4157, its individualized neoantigen therapy (int), in combination with keytruda®, for high-risk melanoma cambridge, ma / accesswire / august 3, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today reported financial results and provided business updates for the second quarter of 2023. "second quarter sales were on target, given the seasonal nature of covid.
MRNA Ratings Summary
MRNA Quant Ranking